Yen C-J - Department of Internal Medicine and Division of Hematology and Oncology, National Cheng Kung University Hospital

基本信息

浏览量：70

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 56 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

401P Vibostolimab Coformulated with Pembrolizumab (vibo/pembro) + Chemotherapy (chemo) As First-Line Treatment for Advanced Esophageal Cancer (ec): Results from Cohort E of the Phase II KEYVIBE-005 Study

C-H. Hsu, R. Dziadziuszko, D.A. Gomez Abreo, S. Aksoy,M. Gil Martín, C. Roderburg,C.J. Yen, A. Arican, P. Cassier,S-A. Im,S-B. Kim, T. Kudo, S. Ochsenreither, M.A.N. Sendur, K. Yonemori, C.I. Rojas, Q. Liu, T. Keenan, J. Healy, M. Kwiatkowski

Annals of Oncology (2024)

引用0浏览0引用

The prognostic power of two-dimensional strain-derived left ventricular myocardial work for all-cause mortality in pancreatic ductal adenocarcinoma patients receiving cancer therapy

Y. Liu, P. Y. Liu,C. J. Yen,Y. S. Shan

European Heart Journalno. Supplement_2 (2023)

引用0浏览0引用

408P Increased EGFR and MET Expression and Corresponding Tumor Microenvironment (TME) Change in Hepatocellular Carcinoma (HCC) Tissues after Sorafenib (sora) Treatment

C. J. Yen, M. Qing, X. Lyu, M. Gormley, J. Curtin, M. Xia, F. Yang, L. Zhou

Annals of oncology (2023): S1624-S1624

引用0浏览0引用

656MO The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study

H. Yao,M.H. Ryu,J. Park,M. Voskoboynik,J.H. Kim, K. Liu,M. Barve, A. Acuna-Villaorduna,S-A. Im,A.C. Roy,L-Y. Bai,C-J. Yen,J. Zhang,V. Ganju, L. Wu, M. Yan,L. Bao,Y. Zhao, S. Rong,E. Song

Annals of Oncology (2023): S461-S462

引用2浏览0引用

Pembrolizumab Monotherapy Versus Chemotherapy in Platinum-Pretreated, Recurrent or Metastatic Nasopharyngeal Cancer (KEYNOTE-122): an Open-Label, Randomized, Phase III Trial

A. T. C. Chan,V. H. F. Lee,R-L Hong,M. -J. Ahn,W. Q. Chong,S. -B. Kim,G. F. Ho,P. B. Caguioa,N. Ngamphaiboon,C. Ho, M. A. S. A. Aziz,Q. S. Ng,C. -J. Yen,N. Soparattanapaisarn,R. K. -C Ngan, S. K. Kho, M. L. A. Tiambeng, T. Yun,V. Sriuranpong,A. P. Algazi, A. Cheng,E. Massarelli,R. F. Swaby,S. Saraf, J. Yuan,L. L. Siu

Annals of oncology（2023）

引用15浏览0WOS引用

412P Multiplex Digital Spatial Profiling (DSP) of Protein Reveals Distinct Immune and Molecular Phenotypes in Hepatocellular Carcinoma

C. J. Yen, M. Qing, Q. Wu, X. Lyu, M. Xia, F. Yang, H. Xu, L. Zhou

ANNALS OF ONCOLOGY (2023): S1625-S1625

引用0浏览0引用

1012P First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression

A-L. Cheng,C-J. Yen,Q. Cheng,C-C. Lin, P. Huang,D. Li, Y. Li, J. Wang, M. Sun,Q. Wen, S. Gu, X. Du, J. Qian,C. Liu, F. Zhang,C. Dai, G. Li, X. Ding,J. Liu,X-P. Chen

Annals of Oncology (2023): S617

引用0浏览0引用

117Tip BGB-HNSCC-201 (NCT05909904): Phase II, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents As First-Line (1L) Treatment in Patients (pts) with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

K.J. Harrington,Y. Guo, R. Haddad, H.R. Kim,C.A. Perez, I. Xiang, H. Li, G. Dong,C.J. Yen, C. Even,L.D. Locati, S. Qiu

Immuno-Oncology and Technology (2023): 100659

引用0浏览0引用

First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors

C. J. Yen, M-C. Liu, J. Fan, C. Sun,P. Peng, X. Du, J. Wang, F. Wei, Z. Gou, X. Tan, D. Wu, F. Wu,C-L. Ho

Annals of Oncology (2023): S1497-S1497

引用0浏览0引用

Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis

D-Y. Oh, Y. Bai,M. H. Ryu, J. Lee, J. Li, S. Luo, H. Pan,Y. Qu, J. Lu, L. Yang,H. Yasui,H. Yabusaki,C. J. Yen,W. W. L. Chan, K. Yamaguchi,K-H. Yeh, L. Yin,S. Bordia,P. Bhagia,S. Y. Rha

ANNALS OF ONCOLOGY (2023): S1526-S1526

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn